<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Microbiol Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">J Microbiol Biotechnol</journal-id><journal-title-group><journal-title>Journal of Microbiology and Biotechnology</journal-title></journal-title-group><issn pub-type="ppub">1017-7825</issn><issn pub-type="epub">1738-8872</issn><publisher><publisher-name>The Korean Society for Microbiology and Biotechnology</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40374547</article-id><article-id pub-id-type="pmc">PMC12099623</article-id>
<article-id pub-id-type="doi">10.4014/jmb.2501.01036</article-id><article-id pub-id-type="publisher-id">jmb-35-e2501036</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject><subj-group><subject>Biotechnology and Bioengineering (BB)</subject><subj-group><subject>Cell Culture and Biomedical Engineering</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Effect of <italic toggle="yes">N</italic>-Glycan Profiles on Binding Affinity of Diagnostic Antibody Produced by Hybridomas in Serum-Free Suspension</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae-Ho</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Dae Eung</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Hoon-Min</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Mi-Jung</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jung Hwa</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>You</surname><given-names>Jungmok</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Mi Kyeong</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Yeon-Gu</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor2" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, <country>Republic of Korea</country></aff><aff id="aff2"><label>2</label>Department of Convergent Biotechnology &#x00026; Advanced Materials Science, Graduate School of Biotechnology, College of Life Science, Kyung Hee University, Yongin-si 17104, <country>Republic of Korea</country></aff><aff id="aff3"><label>3</label>College of Pharmacy, Chungbuk National University, Cheongju 28160, <country>Republic of Korea</country></aff><aff id="aff4"><label>4</label>Department of Bioprocess Engineering, KRIBB School of Biotechnology, University of Science and Technology (UST), Daejeon 34113, <country>Republic of Korea</country></aff><aff id="aff5"><label>5</label>Department of R&#x00026;D, Boditech Med Inc., Chuncheon 24398, <country>Republic of Korea</country></aff><author-notes><corresp id="cor1">
<label>*</label>Corresponding authors MK Lee E-mail: <email xlink:href="mklee@chungbuk.ac.kr">mklee@chungbuk.ac.kr</email></corresp><corresp id="cor2">
YG Kim E-mail: <email xlink:href="ygkim@kribb.re.kr">ygkim@kribb.re.kr</email>
</corresp><fn id="fn1" fn-type="equal"><label>&#x02020;</label><p>Tae-Ho Kim and Dae Eung Kim contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>35</volume><elocation-id>e2501036</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 by the authors. Licensee KMB</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is an open access article distributed under the terms and conditions of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution (CC BY) license</ext-link></license-p></license></permissions><abstract><p>Serum-free suspension culture for hybridomas is one of the important key steps for efficient diagnostic antibody production while maintaining protein quality and function. Based on the importance of <italic toggle="yes">N</italic>-glycan profiles in therapeutic antibody production in mammalian cells, the effect of changes in the <italic toggle="yes">N</italic>-glycan profiles on the function of diagnostic antibody must also be validated. To investigate the influence of diagnostic antibodies with different <italic toggle="yes">N</italic>-glycan profiles on the binding affinity with target antigens, four glycosylation regulators, tunicamycin, Bis-Tris, galactose, and <italic toggle="yes">N</italic>-acetylmannosamine, were administered separately to diagnostic antibody-producing hybridomas cultures. Supplementation with these four glycosylation modulators inhibited glycosylation and increased mannosylation, galactosylation, and sialylation in serum-free suspended hybridomas. In particular, the diagnostic antibody produced from a culture with tunicamycin exhibited a significant increase in the aglycosylated form compared with those without tunicamycin or with other glycosylation modulators. Surprisingly, diagnostic antibody with different <italic toggle="yes">N</italic>-glycan compositions did not significantly affect binding affinity with the target antigen and even aglycosylated antibodies did not affect binding affinity. Taken together, the results indicate that the change in the <italic toggle="yes">N</italic>-glycan profile of the diagnostic antibody produced in serum-free suspension hybridomas in an altered culture environment did not significantly affect their biological function, which provides valuable insight for the production and quality control of diagnostic antibody.</p></abstract><kwd-group><kwd>Hybridomas</kwd><kwd>diagnostic antibody</kwd><kwd>suspension culture</kwd><kwd>glycosylation</kwd><kwd>binding affinity</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hybridomas are cells created by the fusion of monoclonal antibody-producing B cells and immortal myeloma cells [<xref rid="ref1" ref-type="bibr">1</xref>]. The combined properties enable the hybridoma to consistently and reliably produce a specific monoclonal antibody derived from B cells. Because of this characteristic of hybridomas, which can produce an unlimited number of identical monoclonal antibodies, they are primarily used in diagnostic areas that require high specificity for specific target antigens [<xref rid="ref2" ref-type="bibr">2</xref>]. One of the main challenges during the production of diagnostic antibody by hybridomas is the suspension culture using serum-free media, which has many advantages over the mouse ascites method-based production and serum-containing adherent-based production [<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref4" ref-type="bibr">4</xref>]. The use of serum-free media prevents contamination with nonspecific monoclonal antibodies derived from mouse ascites and fetal bovine serum [<xref rid="ref4" ref-type="bibr">4</xref>]. Adherent cultures are limited by the surface area available for cell attachment; however, suspension cultures of hybridomas are easier to scale up and achieve higher cell concentrations, which effectively increases volumetric antibody production [<xref rid="ref5" ref-type="bibr">5</xref>]. Therefore, adapting hybridomas to serum-free suspension culture is a prerequisite for the efficient production of diagnostic antibody while maintaining protein quality.</p><p>For canonical antibody production using mammalian cells, the <italic toggle="yes">N</italic>-glycosylation pattern within the Fc region of the canonical antibody structure is significantly affected by the culture environment [<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>]. For example, in recombinant Chinese hamster ovary (rCHO) cell cultures for the production of therapeutic proteins, including canonical antibody, impaired glycosylation can occur under various stress culture conditions [<xref rid="ref8" ref-type="bibr">8</xref>, <xref rid="ref9" ref-type="bibr">9</xref>]. Stressful culture conditions can induce cell death by membrane disruption, resulting in the release of enzymes, such as proteases and glycosidases, which disrupt the glycosylation of extracellularly produced glycoproteins [<xref rid="ref10" ref-type="bibr">10</xref>]. Because <italic toggle="yes">N</italic>-glycosylation for the biological function of therapeutic glycoproteins is important, the cell culture process for rCHO cells must be optimized, including feeding strategies for maintaining high cell viability to mitigate cell death and prevent <italic toggle="yes">N</italic>-glycan damage [<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr"/>-<xref rid="ref13" ref-type="bibr">13</xref>]. Supplementing rCHO cell culture with various nucleotide sugar precursors has been done to improve the <italic toggle="yes">N</italic>-glycosylation of therapeutic glycoproteins [<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr"/><xref rid="ref16" ref-type="bibr"/>-<xref rid="ref17" ref-type="bibr">17</xref>]. In contrast to efforts to modulate <italic toggle="yes">N</italic>-glycans in therapeutic canonical antibody production from mammalian cells, there is little evidence that the <italic toggle="yes">N</italic>-glycan profile of diagnostic antibodies produced in hybridomas is responsible for their function, particularly their binding affinity with the target antigen.</p><p>In this study, we examined the effect of diagnostic antibodies with different <italic toggle="yes">N</italic>-glycan profiles on their binding affinity with the target antigen. Diagnostic monoclonal antibodies with diverse <italic toggle="yes">N</italic>-glycan profiles were produced in serum-free suspension cultures of hybridomas supplemented with various glycosylation modulators. We analyzed <italic toggle="yes">N</italic>-glycan formation and intracellular nucleotide sugar levels by hydrophilic interaction high-performance liquid chromatography (HPLC) and ion-pair reversed-phase HPLC.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Cell line, Culture Maintenance, and Glycosylation Modulator Treatment</title><p>The diagnostic antibody-producing hybridomas, provided by Med Inc. (Republic of Korea), were initially maintained in an adherent culture using Dulbecco's modified Eagle's medium (Hyclone, USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific, USA). The hybridomas were then grown in a serum-free suspension culture using a Climo-shaking CO<sub>2</sub> incubator (Adolf K&#x000fc;hner, Switzerland) at 110 rpm, 70% humidity, and 37&#x000b0;C. SFM4CHO (Hyclone) supplemented with 4 mM glutamine was used for culture maintenance.</p><p>Exponentially growing cells were seeded at a concentration of 3 &#x000d7; 10<sup>5</sup> cells/ml in 125 ml Erlenmeyer flasks (Corning, USA) containing 30 ml of SFM4CHO supplemented with 4 mM glutamine and Cell Boost 6 (Hyclone). After 2 days, 1 &#x003bc;g/ml tunicamycin (Sigma-Aldrich, USA), 10 mM Bis-Tris (Sigma-Aldrich), 20 mM galactose (Sigma-Aldrich), and 20 mM <italic toggle="yes">N</italic>-acetylmannosamine (ManNAc; Sigma-Aldrich) were added individually to the culture as glycosylation modulators.</p></sec><sec><title>Cell Concentration, Viability, Antibody Assay, and Amino Acid Analysis</title><p>The cell concentration and viability were evaluated using a Cedex HiRes analyzer (Roche Diagnostics, Switzerland) based on the trypan blue dye exclusion method. The concentration of the secreted diagnostic antibody in the culture supernatant was quantitated using a Cedex Bio analyzer (Roche Diagnostics) based on the manufacturer&#x02019;s instructions. Amino acid concentrations in the spent media were measured using a REBEL cell culture analyzer (908 Devices, USA), a microfluidic capillary electrophoresis combined with high-pressure mass spectrometry. The samples were analyzed in technical triplicates with calibration curves automatically generated from triplicate analysis of the standards.</p></sec><sec><title><italic toggle="yes">N</italic>-Glycan Analysis of the Diagnostic Antibody</title><p>The diagnostic antibody was purified from the cell culture supernatants by protein G chromatography using a HiTrap Protein G HP (Cytiva, UK) and a liquid chromatography system (&#x000c4;KTA pure 25 L; Cytiva). The <italic toggle="yes">N</italic>-glycans of the purified diagnostic antibody were enzymatically released using PNGase F (Roche Diagnostics) and fluorescently labeled with 2-aminobenzamide (Sigma-Aldrich). The labeled <italic toggle="yes">N</italic>-glycans were injected directly into an AdvanceBio Glycan Map column (2.7 &#x003bc;m, 4.6 mm &#x000d7; 150 mm; Agilent Technologies, USA) connected to an Ultra HPLC (UHPLC) system (1290 Infinity II Bio LC system; Agilent Technologies). The labeled <italic toggle="yes">N</italic>-glycans were monitored using a fluorescence detector at an excitation wavelength of 260 nm and an emission wavelength of 430 nm.</p></sec><sec><title>Quantitation of the Intracellular Nucleotide Sugars</title><p>Intracellular nucleotide sugars were analyzed as previously described [<xref rid="ref18" ref-type="bibr">18</xref>]. Briefly, ion-pair reversed-phase chromatography was used for quantitating intracellular nucleotide sugars, which were detected at 254 nm using a Waters ACQUITY Premier HSS T3 column with VanGuard FIT (150 mm; Waters, USA) connected to a UHPLC system (1290 Infinity II Bio LC system; Agilent Technologies). Peak identification of the nucleotide sugars was achieved using a standard mixture containing the following nucleotide sugars: CMP-sialic acid (CMP-SA), UDP-galactose (UDP-Gal), UDP-glucose (UDP-Glc), UDP-<italic toggle="yes">N</italic>-acetylglucosamine (UDP-GlcNAc), and GDP-fucose (GDP-Fuc). The integrated peak areas of the standard mixture were calculated using the OpenLab CDS ChemStation software (Agilent Technologies) following UHPLC analysis.</p></sec><sec><title>ELISA for Diagnostic Antibody with Specific Target Antigen</title><p>The purified diagnostic antibody was tested with the target antigen provided by Boditech Med Inc., (Republic of Korea) using a conventional ELISA, as described previously [<xref rid="ref19" ref-type="bibr">19</xref>]. Briefly, 96-well plates (Corning) were coated with antigen in carbonate-bicarbonate buffer and incubated overnight at 4&#x000b0;C. After five washes with phosphate buffered saline (PBS; Sigma-Aldrich) containing 0.1% Tween 20 (Sigma-Aldrich), the plates were blocked with PBS containing 1% bovine serum albumin (Sigma-Aldrich). Synthetic buffer (WellChampion; Kem-En-Tec, Denmark) was then added to stabilize the wells, followed by incubation for 1 h at 37&#x000b0;C. Various concentrations of the purified diagnostic antibody and positive quality control materials, provided by Boditech Med Inc., were added to the wells and incubated for 1 h at 37&#x000b0;C. After washing, horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary antibody (KPL, USA) in HRP stabilizer (Kem-En-Tec) was added and incubated for 1 h at 37&#x000b0;C. The peroxidase reaction was visualized by adding TMB ONE (Kem-En-Tec) for 15 min at 25&#x000b0;C. Color development was stopped with the addition of H<sub>2</sub>SO<sub>4</sub>. The absorbance was measured at 450 nm.</p></sec><sec><title>Statistical Analysis</title><p>The results are expressed as mean &#x000b1; standard deviation. The data were analyzed using a two-tailed student&#x02019;s <italic toggle="yes">t</italic>-test when appropriate. Differences between means were considered significant at <italic toggle="yes">p</italic> &#x02264; 0.05.</p></sec></sec><sec sec-type="results|discussion"><title>Results and Discussion</title><sec><title>Effects of Glycosylation Modulators on Cell Growth, Antibody Production, and Metabolism</title><p>To determine the effect of glycosylation modulators on cell growth and antibody production in hybridomas, a diagnostic antibody-producing hybridomas was adapted to serum-free suspension culture and cultivated with glycosylation modulators. We selected four glycosylation modulators, tunicamycin, Bis-Tris, galactose, and ManNAc, which are known to inhibit glycosylation or increase mannosylation, galactosylation, and sialylation in mammalian cells, respectively [<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr"/>-<xref rid="ref21" ref-type="bibr">21</xref>]. Cells without glycosylation modulators were also cultured as a control.</p><p><xref rid="F1" ref-type="fig">Fig. 1</xref> shows the profiles of viable cell concentration, viability, and diagnostic antibody concentration of serum-free suspended hybridomas during the culture with or without glycosylation modulators. From the serum-containing adherent culture to the serum-free suspension culture mode for diagnostic antibody-producing hybridomas, the maximum viable cell concentration and final antibody production increased by 4.5- and 5.7-fold, respectively (<xref rid="F1" ref-type="fig">Fig. 1A</xref>). As shown in <xref rid="F1" ref-type="fig">Fig. 1B</xref>, the culture treated with tunicamycin exhibited a marked decrease in cell viability and diagnostic antibody production. The same amount of solvent (DMSO) used to prepare the tunicamycin solution did not show any detrimental effects (<italic toggle="yes">p</italic> &#x0003e; 0.05) (data not shown). The remaining three glycosylation modulators increased diagnostic antibody production without improving cell growth, indicating that these treatments are effective at enhancing specific protein productivity (<italic toggle="yes">q</italic><sub>p</sub>). Although the extent of the effectiveness varied depending on optimized culture conditions, the trends were similar to those of previous studies of the glycosylation modulators used in this study [<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr"/>-<xref rid="ref21" ref-type="bibr">21</xref>].</p><p><xref rid="F2" ref-type="fig">Fig. 2</xref> shows the specific consumption rates of individual amino acids for serum-free suspended hybridomas during culture with or without glycosylation modulators from days 2 to 3, as shown in <xref rid="F1" ref-type="fig">Fig. 1</xref>. Tunicamycin treatment resulted in a significant accumulation of alanine, arginine, glycine, serine, and tryptophan, in contrast to the culture with or without the other three glycosylation modulators. It has been reported that the accumulation of serine is attributed to decreased cell growth [<xref rid="ref22" ref-type="bibr">22</xref>]. In cultures treated with Bis-Tris, galactose, and ManNAc, the consumption of most amino acids showed varying trends during culture without these, except for leucine. This variation in amino acid metabolism is likely the result of changes in diagnostic antibody productivity and glycosylation patterns.</p></sec><sec><title>Effect of Glycosylation Modulators on <italic toggle="yes">N</italic>-Glycosylation of Diagnostic Antibody</title><p>To evaluate the effect of glycosylation modulators on the <italic toggle="yes">N</italic>-glycan of diagnostic monoclonal antibody from a hybridomas culture, the antibody produced on day 3 was purified by protein G chromatography (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Cell culture supernatants with viability greater than 80% were harvested to avoid the possibility of impaired glycosylation from sialidase released following cell membrane disruption. The major <italic toggle="yes">N</italic>-glycans released from the diagnostic antibody following PNGase F incubation were analyzed by hydrophilic interaction HPLC column and classified into six groups (G0, G0F, Man, G1F, G2F, G2S1F, and G2S2F) based on their structure.</p><p><xref rid="F3" ref-type="fig">Fig. 3</xref> shows the expression pattern of the diagnostic antibody as determined by SDS-PAGE analysis and the proportion of major <italic toggle="yes">N</italic>-glycans, which were calculated by integrating the area of each group following UHPLC analysis. The diagnostic antibody produced from the culture with tunicamycin showed a significant increase in the aglycosylated form compared with that treated with or without other glycosylation modulators (<xref rid="F3" ref-type="fig">Fig. 3A</xref>); however, the <italic toggle="yes">N</italic>-glycan profile was similar to that of the control culture (<xref rid="F3" ref-type="fig">Fig. 3B</xref>). Bis-Tris treatment significantly increased the proportion of highly mannosylated <italic toggle="yes">N</italic>-glycans to 42.27% &#x000b1; 0.5% compared with the control cultures (&#x0003c;0.5%). The sum of the proportions of biantennary galactosylation (G2F, G2S1F, and G2S2F) was 16.22% &#x000b1; 0.82% following galactose supplementation, which was the highest and higher than that of the control culture (10.04% &#x000b1; 0.81%) (<italic toggle="yes">p</italic> &#x02264; 0.05). Compared with the control culture (2.79% &#x000b1; 0.2%), the sum of the proportions of biantennary sialylation (G2S1F, and G2S2F) significantly increased (4.85% &#x000b1; 0.58%) following the addition of ManNAc (<italic toggle="yes">p</italic> &#x02264; 0.05). Taken together, supplementation with the four glycosylation modulators inhibited glycosylation and increased mannosylation, galactosylation, and sialylation in the diagnostic antibody-producing hybridomas.</p></sec><sec><title>Effect of Glycosylation Modulators on Intracellular Nucleotide Sugar Pools</title><p>The amount of intracellular nucleotide sugar pools in mammalian cells is important for the <italic toggle="yes">N</italic>-glycosylation process and its availability greatly affects the glycan complexity and final glycosylation profile [<xref rid="ref23" ref-type="bibr">23</xref>]. To determine whether the addition of glycosylation modulators affected the concentration of intracellular nucleotide sugar in the hybridomas, we quantified the amount of six intracellular nucleotide sugar pools using ion-pair reversed-phase HPLC.</p><p><xref rid="F4" ref-type="fig">Fig. 4</xref> shows the relative amounts of the six intracellular nucleotide sugars (CMP-SA, UDP-Gal, UDP-GalNAc, UDP-Glc, UDP-GlcNAc, and GDP-Fuc) for the hybridomas in the presence or absence of the four glycosylation modulators on day 3. The fold-change values were calculated based on the number of nucleotide sugars measured in the cell lysates on day 3 of the control culture. Consistent with a previous study examining the effect of ManNAc in rCHO cells [<xref rid="ref20" ref-type="bibr">20</xref>], ManNAc addition significantly increased the concentration of CMP-SA, a nucleotide sugar directly used for sialylation in hybridomas compared with the control culture. Notably, a significant decrease in UDP-Gal, UDP-GalNAc, UDP-Glc, and GDP-Fuc was observed in the tunicamycin-treated culture, which may have been related to aglycosylated antibody production. Treatment with Bis-Tris increased the proportion of highly mannosylated <italic toggle="yes">N</italic>-glycans, whereas there was no significant change in the concentration of intracellular nucleotide sugars (<italic toggle="yes">p</italic> &#x0003e; 0.05).</p></sec><sec><title>Binding Affinity of the Diagnostic Antibody with Various <italic toggle="yes">N</italic>-Glycosylation Patterns</title><p>To determine whether the diagnostic antibody with various major <italic toggle="yes">N</italic>-glycan profiles affects the binding affinity with the target antigen, we performed an ELISA with the purified diagnostic antibody and positive quality control materials produced by the mouse ascites method.</p><p><xref rid="F5" ref-type="fig">Fig. 5</xref> shows the results of the binding affinity assay in the presence of different diagnostic antibody concentrations produced from cultures with and without the four other glycosylation modulators. The pattern of the binding affinity assay with the diagnostic antibody produced from serum-free suspended hybridomas attempted was similar to that from mouse ascites, which was used as a positive control (data not shown). Regardless of the type of <italic toggle="yes">N</italic>-glycan profile, the binding affinity between the diagnostic antibody and its target antigen was highly dose-dependent. Unexpectedly, the type of <italic toggle="yes">N</italic>-glycan profile did not have a significant effect on binding to the target antigen and even the aglycosylated antibody exhibited a similar binding affinity. Taken together, the results indicate that the modulation of the <italic toggle="yes">N</italic>-glycan profile of the antibody by the altered culture environment in serum-free suspension hybridomas does not affect its function in a diagnostic assay.</p><p>The use of serum-free suspension culture for hybridomas in the production of diagnostic antibody has the benefits of high productivity and the elimination of contamination from nonspecific antibodies that are present in serum. Generally, it is very difficult to maintain the glycosylation of an antibody produced in serum-free suspension cultures of mammalian cells, as it is dependent on the culture environment and prone to cell death. We demonstrated that the <italic toggle="yes">N</italic>-glycan profile of the diagnostic antibody produced by serum-free suspended hybridomas is not an important factor in binding affinity, which is a key factor for diagnostic assay (<xref rid="F4" ref-type="fig">Fig. 4</xref>). These results will enable us to utilize culture conditions that previously had negative effects on <italic toggle="yes">N</italic>-glycans in rCHO cell culture, for antibody production. For example, sodium butyrate is a well-known additive that enhances <italic toggle="yes">q</italic><sub>p</sub>, but it is not widely used in the production of therapeutic proteins in rCHO cell culture because of its negative impact on <italic toggle="yes">N</italic>-glycosylation [<xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref25" ref-type="bibr">25</xref>]. Because there is no relationship between <italic toggle="yes">N</italic>-glycosylation and the activity of the diagnostic antibody, we can focus on maximizing its production using various additives and culture processes that are not used for rCHO cell culture.</p><p>Glycosylation of the Fc region in the therapeutic monoclonal antibody significantly affects the Fc-mediated effector functions of the antibody, such as antibody-dependent and complement-dependent cytotoxicity [<xref rid="ref26" ref-type="bibr">26</xref>]. Therefore, precise control of glycosylation in therapeutic monoclonal antibody is necessary to maintain consistent function and effectiveness. In contrast, the diagnostic monoclonal antibody should be optimized for antigen binding affinity and specificity of the Fab region rather than the immune effect of the Fc region. Although it can occur in the Fab and Fc regions, glycosylation of the monoclonal antibody predominantly exists in the Fc region [<xref rid="ref27" ref-type="bibr">27</xref>]. Therefore, glycosylation is not likely to significantly affect the diagnostic use of the monoclonal antibody, which is consistent with our findings. These results suggest that the importance of glycosylation of the Fc region in the monoclonal antibody may vary depending on the purpose for which the antibody is used.</p><p>In this study, the introduction of serum-free suspension culture resulted in a 5.7-fold increase in diagnostic antibody production in hybridomas (<xref rid="F1" ref-type="fig">Fig. 1</xref>); however, the volumetric titer of the diagnostic antibody produced from the hybridomas tends to be relatively low, less than 1 g/L, compared with the high titers achieved (10 g/L) for recombinant therapeutic antibody in rCHO cells using high expression vectors. Recent studies successfully sequenced the nucleotides of antibody from hybridomas and produced them in the form of recombinant antibody in mammalian cells [<xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr"/>-<xref rid="ref30" ref-type="bibr">30</xref>]. The recombinant antibody produced in mammalian cells is expected to differ in <italic toggle="yes">N</italic>-glycan composition from the antibody produced in hybridomas in our study; however, it is expected to have similar biological function when used as a diagnostic antibody. Based on our finding, establishing recombinant diagnostic antibody-producing mammalian cells with the same antibody binding affinity as hybridomas is an effective method to achieve high titers of diagnostic antibody.</p><p>In conclusion, we produced a diagnostic antibody with various <italic toggle="yes">N</italic>-glycan profiles from a serum-free suspension hybridomas culture with glycosylation modulators. We also demonstrated that <italic toggle="yes">N</italic>-glycosylation of diagnostic antibody did not significantly affect binding affinity, which is useful for the efficient production and quality control of diagnostic antibody.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the Korea Medical Device Development Fund grant funded by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health &#x00026; Welfare, the Ministry of Food and Drug Safety (Project Number: 1711195280, RS-2020-KD000021) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (Project Number: KGM1262511).</p></ack><fn-group><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold>
</p><p>The authors have no financial conflicts of interest to declare.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sait</surname><given-names>A</given-names></name>
<name><surname>Korkmaz</surname><given-names>S</given-names></name>
<name><surname>Parmaks&#x00131;z</surname><given-names>A</given-names></name>
<name><surname>Erba&#x0015f;</surname><given-names>O</given-names></name>
</person-group><year>2022</year><article-title>Hybridoma technology for the production of monoclonal antibodies</article-title><source>D J. Med. Sci.</source><volume>8</volume><fpage>141</fpage><lpage>149</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitra</surname><given-names>S</given-names></name>
<name><surname>Tomar</surname><given-names>PC</given-names></name>
</person-group><year>2021</year><article-title>Hybridoma technology; advancements, clinical significance, and future aspects</article-title><source>J. Genet. Eng. Biotechnol.</source><volume>19</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s43141-021-00264-6</pub-id><!--<pub-id pub-id-type="pmcid">PMC8521504</pub-id>--><pub-id pub-id-type="pmid">34661773</pub-id>
</element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Birch</surname><given-names>JR</given-names></name>
<name><surname>Arathoon</surname><given-names>R</given-names></name>
</person-group><year>1990</year><article-title>Suspension culture of mammalian cells</article-title><source>Bioprocess Technol.</source><volume>10</volume><fpage>251</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1201/9780203749166-10</pub-id><pub-id pub-id-type="pmid">1367062</pub-id>
</element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glassy</surname><given-names>MC</given-names></name>
<name><surname>Tharakan</surname><given-names>JP</given-names></name>
<name><surname>Chau</surname><given-names>PC</given-names></name>
</person-group><year>1988</year><article-title>Serum-free media in hybridoma culture and monoclonal antibody production</article-title><source>Biotechnol. Bioeng.</source><volume>32</volume><fpage>1015</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1002/bit.260320809</pub-id><pub-id pub-id-type="pmid">18587819</pub-id>
</element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bilodeau</surname><given-names>A</given-names></name>
</person-group><year>2024</year><article-title>The pros and cons of adherent versus suspension cell culture</article-title><source>Biopharm. Int.</source><volume>37</volume><fpage>18</fpage><lpage>22</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hossler</surname><given-names>P</given-names></name>
<name><surname>Khattak</surname><given-names>SF</given-names></name>
<name><surname>Li</surname><given-names>ZJ</given-names></name>
</person-group><year>2009</year><article-title>Optimal and consistent protein glycosylation in mammalian cell culture</article-title><source>Glycobiology</source><volume>19</volume><fpage>936</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwp079</pub-id><pub-id pub-id-type="pmid">19494347</pub-id>
</element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S-M</given-names></name>
<name><surname>Chang</surname><given-names>K-H</given-names></name>
<name><surname>Oh</surname><given-names>DJ</given-names></name>
</person-group><year>2018</year><article-title>Effect of environmental parameters on glycosylation of recombinant immunoglobulin G produced from recombinant CHO cells</article-title><source>Biotechnol. Bioprocess Eng.</source><volume>23</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s12257-018-0109-8</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ha</surname><given-names>TK</given-names></name>
<name><surname>Kim</surname><given-names>D</given-names></name>
<name><surname>Kim</surname><given-names>CL</given-names></name>
<name><surname>Grav</surname><given-names>LM</given-names></name>
<name><surname>Lee</surname><given-names>GM</given-names></name>
</person-group><year>2022</year><article-title>Factors affecting the quality of therapeutic proteins in recombinant Chinese hamster ovary cell culture</article-title><source>Biotechnol. Adv.</source><volume>54</volume><elocation-id>107831</elocation-id><pub-id pub-id-type="doi">10.1016/j.biotechadv.2021.107831</pub-id><pub-id pub-id-type="pmid">34480988</pub-id>
</element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senger</surname><given-names>RS</given-names></name>
<name><surname>Karim</surname><given-names>MN</given-names></name>
</person-group><year>2003</year><article-title>Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue&#x02010;type plasminogen activator protein</article-title><source>Biotechnol. Prog.</source><volume>19</volume><fpage>1199</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1021/bp025715f</pub-id><pub-id pub-id-type="pmid">12892482</pub-id>
</element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sung</surname><given-names>YH</given-names></name>
<name><surname>Hwang</surname><given-names>SJ</given-names></name>
<name><surname>Lee</surname><given-names>GM</given-names></name>
</person-group><year>2005</year><article-title>Influence of down-regulation of caspase-3 by siRNAs on sodium-butyrate-induced apoptotic cell death of Chinese hamster ovary cells producing thrombopoietin</article-title><source>Metab. Eng.</source><volume>7</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2005.08.001</pub-id><pub-id pub-id-type="pmid">16169764</pub-id>
</element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khattak</surname><given-names>SF</given-names></name>
<name><surname>Xing</surname><given-names>Z</given-names></name>
<name><surname>Kenty</surname><given-names>B</given-names></name>
<name><surname>Koyrakh</surname><given-names>I</given-names></name>
<name><surname>Li</surname><given-names>ZJ</given-names></name>
</person-group><year>2010</year><article-title>Feed development for fed&#x02010;batch CHO production process by semisteady state analysis</article-title><source>Biotechnol. Prog.</source><volume>26</volume><fpage>797</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1002/btpr.362</pub-id><pub-id pub-id-type="pmid">20014108</pub-id>
</element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Rodriguez</surname><given-names>S</given-names></name>
<name><surname>Ram&#x000ed;rez-Lira</surname><given-names>MdJ</given-names></name>
<name><surname>Trujillo-Rold&#x000e1;n</surname><given-names>MA</given-names></name>
<name><surname>Valdez-Cruz</surname><given-names>NA</given-names></name>
</person-group><year>2020</year><article-title>Nutrient supplementation strategy improves cell concentration and longevity, monoclonal antibody production and lactate metabolism of Chinese hamster ovary cells</article-title><source>Bioengineered.</source><volume>11</volume><fpage>463</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1080/21655979.2020.1744266</pub-id><!--<pub-id pub-id-type="pmcid">PMC7161567</pub-id>--><pub-id pub-id-type="pmid">32223359</pub-id>
</element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>S</given-names></name>
<name><surname>Ahmed</surname><given-names>W</given-names></name>
<name><surname>Mohsin</surname><given-names>A</given-names></name>
<name><surname>Guo</surname><given-names>M</given-names></name>
</person-group><year>2021</year><article-title>Continuous feeding reduces the generation of metabolic byproducts and increases antibodies expression in Chinese hamster ovary-K1 cells</article-title><source>Life</source><volume>11</volume><fpage>945</fpage><pub-id pub-id-type="doi">10.3390/life11090945</pub-id><!--<pub-id pub-id-type="pmcid">PMC8469772</pub-id>--><pub-id pub-id-type="pmid">34575094</pub-id>
</element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gramer</surname><given-names>MJ</given-names></name>
<name><surname>Eckblad</surname><given-names>JJ</given-names></name>
<name><surname>Donahue</surname><given-names>R</given-names></name>
<name><surname>Brown</surname><given-names>J</given-names></name>
<name><surname>Shultz</surname><given-names>C</given-names></name>
<name><surname>Vickerman</surname><given-names>K</given-names></name>
<etal/>
</person-group><year>2011</year><article-title>Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose</article-title><source>Biotechnol. Bioeng.</source><volume>108</volume><fpage>1591</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1002/bit.23075</pub-id><pub-id pub-id-type="pmid">21328321</pub-id>
</element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JH</given-names></name>
<name><surname>Reier</surname><given-names>J</given-names></name>
<name><surname>Heffner</surname><given-names>KM</given-names></name>
<name><surname>Barton</surname><given-names>C</given-names></name>
<name><surname>Spencer</surname><given-names>D</given-names></name>
<name><surname>Schmelzer</surname><given-names>AE</given-names></name>
<etal/>
</person-group><year>2017</year><article-title>Production and characterization of active recombinant human factor II with consistent sialylation</article-title><source>Biotechnol. Bioeng.</source><volume>114</volume><fpage>1991</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1002/bit.26317</pub-id><pub-id pub-id-type="pmid">28436027</pub-id>
</element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Fan</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Hu</surname><given-names>D</given-names></name>
<name><surname>Deng</surname><given-names>X</given-names></name>
<etal/>
</person-group><year>2015</year><article-title>Galactose supplementation enhance sialylation of recombinant Fc-fusion protein in CHO cell: an insight into the role of galactosylation in sialylation</article-title><source>World J. Microbiol. Biotechnol.</source><volume>31</volume><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1007/s11274-015-1864-8</pub-id><pub-id pub-id-type="pmid">25931375</pub-id>
</element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>NS</given-names></name>
<name><surname>Wati</surname><given-names>L</given-names></name>
<name><surname>Nissom</surname><given-names>PM</given-names></name>
<name><surname>Feng</surname><given-names>HT</given-names></name>
<name><surname>Lee</surname><given-names>MM</given-names></name>
<name><surname>Yap</surname><given-names>MG</given-names></name>
</person-group><year>2010</year><article-title>An investigation of intracellular glycosylation activities in CHO cells: effects of nucleotide sugar precursor feeding</article-title><source>Biotechnol. Bioeng.</source><volume>107</volume><fpage>321</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1002/bit.22812</pub-id><pub-id pub-id-type="pmid">20506284</pub-id>
</element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>HM</given-names></name>
<name><surname>Park</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>TH</given-names></name>
<name><surname>Kim</surname><given-names>HS</given-names></name>
<name><surname>Kim</surname><given-names>DE</given-names></name>
<name><surname>Lee</surname><given-names>MK</given-names></name>
<etal/>
</person-group><year>2024</year><article-title>Effects of autophagy-inhibiting chemicals on sialylation of Fcfusion glycoprotein in recombinant CHO cells</article-title><source>Appl. Microbiol. Biotechnol.</source><volume>108</volume><fpage>224</fpage><pub-id pub-id-type="doi">10.1007/s00253-024-13059-9</pub-id><!--<pub-id pub-id-type="pmcid">PMC10879319</pub-id>--><pub-id pub-id-type="pmid">38376550</pub-id>
</element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brantley</surname><given-names>TJ</given-names></name>
<name><surname>Mitchelson</surname><given-names>FG</given-names></name>
<name><surname>Khattak</surname><given-names>SF</given-names></name>
</person-group><year>2021</year><article-title>A class of low&#x02010;cost alternatives to kifunensine for increasing high mannose N&#x02010;linked glycosylation for monoclonal antibody production in Chinese hamster ovary cells</article-title><source>Biotechnol. Prog.</source><volume>37</volume><elocation-id>e3076</elocation-id><pub-id pub-id-type="doi">10.1002/btpr.3076</pub-id><pub-id pub-id-type="pmid">32888259</pub-id>
</element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>DI</given-names></name>
</person-group><year>1998</year><article-title>Improvement of interferon&#x02010;&#x003b3; sialylation in Chinese hamster ovary cell culture by feeding of N&#x02010;acetylmannosamine</article-title><source>Biotechnol. Bioeng.</source><volume>58</volume><fpage>642</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0290(19980620)58:6&#x0003c;642::AID-BIT10&#x0003e;3.3.CO;2-A</pub-id><pub-id pub-id-type="pmid">10099302</pub-id>
</element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almahayni</surname><given-names>K</given-names></name>
<name><surname>Spiekermann</surname><given-names>M</given-names></name>
<name><surname>Fiore</surname><given-names>A</given-names></name>
<name><surname>Yu</surname><given-names>G</given-names></name>
<name><surname>Pedram</surname><given-names>K</given-names></name>
<name><surname>M&#x000f6;ckl</surname><given-names>L</given-names></name>
</person-group><year>2022</year><article-title>Small molecule inhibitors of mammalian glycosylation</article-title><source>Matrix Biol. Plus</source><volume>16</volume><elocation-id>100108</elocation-id><pub-id pub-id-type="doi">10.1016/j.mbplus.2022.100108</pub-id><!--<pub-id pub-id-type="pmcid">PMC9713294</pub-id>--><pub-id pub-id-type="pmid">36467541</pub-id>
</element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duarte</surname><given-names>TM</given-names></name>
<name><surname>Carinhas</surname><given-names>N</given-names></name>
<name><surname>Barreiro</surname><given-names>LC</given-names></name>
<name><surname>Carrondo</surname><given-names>MJ</given-names></name>
<name><surname>Alves</surname><given-names>PM</given-names></name>
<name><surname>Teixeira</surname><given-names>AP</given-names></name>
</person-group><year>2014</year><article-title>Metabolic responses of CHO cells to limitation of key amino acids</article-title><source>Biotechnol. Bioeng.</source><volume>111</volume><fpage>2095</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1002/bit.25266</pub-id><pub-id pub-id-type="pmid">24771076</pub-id>
</element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naik</surname><given-names>HM</given-names></name>
<name><surname>Majewska</surname><given-names>NI</given-names></name>
<name><surname>Betenbaugh</surname><given-names>MJ</given-names></name>
</person-group><year>2018</year><article-title>Impact of nucleotide sugar metabolism on protein <italic toggle="yes">N</italic>-glycosylation in Chinese Hamster Ovary (CHO) cell culture</article-title><source>Curr. Opin. Chem. Eng.</source><volume>22</volume><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.coche.2018.10.002</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>BS</given-names></name>
<name><surname>Jeong</surname><given-names>YT</given-names></name>
<name><surname>Chang</surname><given-names>KH</given-names></name>
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
</person-group><year>2001</year><article-title>Effect of sodium butyrate on glycosylation of recombinant erythropoietin</article-title><source>J. Microbiol. Biotechnol.</source><volume>11</volume><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1007/978-94-010-0369-8_46</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sung</surname><given-names>YH</given-names></name>
<name><surname>Song</surname><given-names>YJ</given-names></name>
<name><surname>Lim</surname><given-names>SW</given-names></name>
<name><surname>Chung</surname><given-names>JY</given-names></name>
<name><surname>Lee</surname><given-names>GM</given-names></name>
</person-group><year>2004</year><article-title>Effect of sodium butyrate on the production, heterogeneity and biological activity of human thrombopoietin by recombinant Chinese hamster ovary cells</article-title><source>J. Biotechnol.</source><volume>112</volume><fpage>323</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2004.05.003</pub-id><pub-id pub-id-type="pmid">15313009</pub-id>
</element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jefferis</surname><given-names>R</given-names></name>
</person-group><year>2005</year><article-title>Glycosylation of recombinant antibody therapeutics</article-title><source>Biotechnol. Prog.</source><volume>21</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1021/bp040016j</pub-id><pub-id pub-id-type="pmid">15903235</pub-id>
</element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jefferis</surname><given-names>R</given-names></name>
</person-group><year>2007</year><article-title>Antibody therapeutics: isotype and glycoform selection</article-title><source>Expert Opin Biol Ther.</source><volume>7</volume><fpage>1401</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1517/14712598.7.9.1401</pub-id><pub-id pub-id-type="pmid">17727329</pub-id>
</element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryu</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>EJ</given-names></name>
<name><surname>Kim</surname><given-names>JK</given-names></name>
<name><surname>Park</surname><given-names>TH</given-names></name>
<name><surname>Kim</surname><given-names>BG</given-names></name>
<name><surname>Jeong</surname><given-names>HJ</given-names></name>
</person-group><year>2022</year><article-title>Development of a CHO cell line for stable production of recombinant antibodies against human MMP9</article-title><source>BMC Biotechnol.</source><volume>22</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s12896-022-00738-6</pub-id><!--<pub-id pub-id-type="pmcid">PMC8903741</pub-id>--><pub-id pub-id-type="pmid">35255869</pub-id>
</element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuniyoshi</surname><given-names>Y</given-names></name>
<name><surname>Maehara</surname><given-names>K</given-names></name>
<name><surname>Iwasaki</surname><given-names>T</given-names></name>
<name><surname>Hayashi</surname><given-names>M</given-names></name>
<name><surname>Semba</surname><given-names>Y</given-names></name>
<name><surname>Fujita</surname><given-names>M</given-names></name>
<etal/>
</person-group><year>2016</year><article-title>Identification of immunoglobulin gene sequences from a small read number of mRNA-seq using hybridomas</article-title><source>PLoS One</source><volume>11</volume><elocation-id>e0165473</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0165473</pub-id><!--<pub-id pub-id-type="pmcid">PMC5082856</pub-id>--><pub-id pub-id-type="pmid">27788226</pub-id>
</element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeLuca</surname><given-names>KF</given-names></name>
<name><surname>Mick</surname><given-names>JE</given-names></name>
<name><surname>DeLuca</surname><given-names>JG</given-names></name>
</person-group><year>2022</year><article-title>Production and purification of recombinant monoclonal antibodies from human cells based on a primary sequence</article-title><source>STAR Protoc.</source><volume>3</volume><elocation-id>101915</elocation-id><pub-id pub-id-type="doi">10.1016/j.xpro.2022.101915</pub-id><!--<pub-id pub-id-type="pmcid">PMC9763751</pub-id>--><pub-id pub-id-type="pmid">36595892</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1</label><caption><title>Profiles of cell growth, viability, and diagnostic antibody production from hybridomas (A) in serumcontaining adherent and serum-free suspended culture mode (B) with and without four glycosylation modulators.</title><p>The arrow indicates the time of glycosylation modulator addition to the culture media. Error bars represent the standard deviations calculated from technical duplicate experiments.</p></caption><graphic xlink:href="jmb-35-e2501036-f1" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2</label><caption><title>Specific consumption rates of amino acids in serum-free suspended hybridomas supplemented with and without four glycosylation modulators.</title><p>The specific consumption rates of the amino acids were calculated from 2&#x02013; 3-day cultures, which were expected before and after the addition of the glycosylation modulators, respectively. Error bars represent the standard deviations calculated from technical triplicate analyses.</p></caption><graphic xlink:href="jmb-35-e2501036-f2" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3</label><caption><title>(A) SDS-PAGE analysis of the purified diagnostic antibody produced from hybridomas supplemented with and without four glycosylation modulators, followed by treatment with (+) and without (&#x02012;) PNGase F.</title><p>The diagnostic antibody was purified by protein G affinity chromatography from the culture supernatants harvested on day 3 with cell viability greater than 80% and treated with PNGase F for the release of <italic toggle="yes">N</italic>-glycans. Equal amounts of proteins were loaded under reducing conditions and the gel was stained with Coomassie brilliant blue. (<bold>B</bold>) Hydrophilic interaction HPLC analysis of the major <italic toggle="yes">N</italic>-glycans obtained from the purified diagnostic antibody from hybridomas on day 3. The relative abundance of six major <italic toggle="yes">N</italic>-glycans (G0, G0F, Man, G1F, G2F, G2S1F, and G2S2F) was obtained from cultures with and without four glycosylation modulators. Error bars represent standard deviations calculated from triplicate experiments. *<italic toggle="yes">p</italic> &#x02264; 0.05, **<italic toggle="yes">p</italic> &#x02264; 0.01, ***<italic toggle="yes">p</italic> &#x02264; 0.001.</p></caption><graphic xlink:href="jmb-35-e2501036-f3" position="float"/></fig><fig position="float" id="F4"><label>Fig. 4</label><caption><title>Fold change in intracellular nucleotide sugars in serum-free suspended hybridomas supplemented with and without four glycosylation modulators.</title><p>Nucleotide sugars were extracted and quantified from cells on day 3 using ion-pair reversed-phase HPLC. The fold change for each nucleotide sugar was calculated based on each nucleotide sugar in the culture without glycosylation modulators. Error bars represent the standard deviations calculated from technical triplicate experiments. *<italic toggle="yes">p</italic> &#x02264; 0.05, **<italic toggle="yes">p</italic> &#x02264; 0.01</p></caption><graphic xlink:href="jmb-35-e2501036-f4" position="float"/></fig><fig position="float" id="F5"><label>Fig. 5</label><caption><title>The binding affinity assay for the purified diagnostic antibody with a specific target antigen.</title><p>The absorbance (OD<sub>450nm</sub>) was measured using a conventional ELISA method with a diagnostic antibody produced from hybridomas in the absence and presence of four glycosylation modulators. Error bars represent standard deviations calculated from data obtained in technical triplicate experiments.</p></caption><graphic xlink:href="jmb-35-e2501036-f5" position="float"/></fig></floats-group></article>